PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 27, 2022New England Journal of Medicine175 citationsOpen Access

Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial

View Full Paper
JLJes S. LindholtRSRikke SøgaardLRLars Melholt Rasmussen

Structured PICO

Does an invitation to undergo comprehensive cardiovascular screening reduce death from any cause in men 65 to 74 years of age?

P
Population
46,611 men 65 to 74 years of age living in 15 Danish municipalities.
I
Intervention
Invitation to undergo comprehensive cardiovascular screening (noncontrast electrocardiography-gated computed tomography to determine coronary-artery calcium score and detect aneurysms and atrial fibrillation; ankle-brachial blood-pressure measurements to detect peripheral artery disease and hypertension; and a blood sample to detect diabetes mellitus and hypercholesterolemia).
C
Comparator
No invitation to undergo screening (control group, unaware of trial-group assignments).
O
Outcome
Death from any causehard clinical

An invitation to undergo comprehensive cardiovascular screening did not significantly reduce all-cause mortality at 5.6 years among men aged 65 to 74 years.

Abstract

BACKGROUND: Limited data suggest a benefit of population-based screening for cardiovascular disease with respect to the risk of death. METHODS: We performed a population-based, parallel-group, randomized, controlled trial involving men 65 to 74 years of age living in 15 Danish municipalities. The participants were randomly assigned in a 1:2 ratio to undergo screening (the invited group) or not to undergo screening (the control group) for subclinical cardiovascular disease. Randomization was based on computer-generated random numbers and stratified according to municipality. Only the control group was unaware of the trial-group assignments. Screening included noncontrast electrocardiography-gated computed tomography to determine the coronary-artery calcium score and to detect aneurysms and atrial fibrillation, ankle-brachial blood-pressure measurements to detect peripheral artery disease and hypertension, and a blood sample to detect diabetes mellitus and hypercholesterolemia. The primary outcome was death from any cause. RESULTS: A total of 46,611 participants underwent randomization. After exclusion of 85 men who had died or emigrated before being invited to undergo screening, there were 16,736 men in the invited group and 29,790 men in the control group; 10,471 of the men in the invited group underwent screening (62.6%). In intention-to-treat analyses, after a median follow-up of 5.6 years, 2106 men (12.6%) in the invited group and 3915 men (13.1%) in the control group had died (hazard ratio, 0.95; 95% confidence interval CI, 0.90 to 1.00; P = 0.06). The hazard ratio for stroke in the invited group, as compared with the control group, was 0.93 (95% CI, 0.86 to 0.99); for myocardial infarction, 0.91 (95% CI, 0.81 to 1.03); for aortic dissection, 0.95 (95% CI, 0.61 to 1.49); and for aortic rupture, 0.81 (95% CI, 0.49 to 1.35). There were no significant between-group differences in safety outcomes. CONCLUSIONS: After more than 5 years, the invitation to undergo comprehensive cardiovascular screening did not significantly reduce the incidence of death from any cause among men 65 to 74 years of age. (Funded by the Southern Region of Denmark and others; DANCAVAS ISRCTN Registry number, ISRCTN12157806.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lindholt et al. (2022) studied this question.

synapsesocial.com/papers/69f53f75e0fbb6efbd203a15https://doi.org/10.1056/nejmoa2208681
Ask AI
Helpful
Bookmark
Share
View Full Paper